| __timestamp | Dynavax Technologies Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 94231000 |
| Thursday, January 1, 2015 | 86943000 | 146394000 |
| Friday, January 1, 2016 | 84493000 | 188272000 |
| Sunday, January 1, 2017 | 64988000 | 166707000 |
| Monday, January 1, 2018 | 74951000 | 401843000 |
| Tuesday, January 1, 2019 | 62331000 | 560909000 |
| Wednesday, January 1, 2020 | 28607000 | 722343000 |
| Friday, January 1, 2021 | 32228000 | 771182000 |
| Saturday, January 1, 2022 | 46600000 | 877090000 |
| Sunday, January 1, 2023 | 54886000 | 877387000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Sarepta Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting trajectories in their R&D spending. From 2014 to 2023, Sarepta's R&D expenses surged by over 830%, reflecting its commitment to pioneering treatments in genetic medicine. In contrast, Dynavax's R&D investment saw a decline of approximately 35%, indicating a strategic shift or potential resource reallocation. Notably, in 2023, Sarepta's R&D expenditure was nearly 16 times that of Dynavax, underscoring its aggressive pursuit of breakthroughs. This divergence highlights the varied strategies within the biotech sector, where some companies double down on innovation, while others may pivot towards commercialization or operational efficiency. As the industry continues to grow, these investment patterns offer a glimpse into the future of medical advancements.
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Dynavax Technologies Corporation
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs CymaBay Therapeutics, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Xencor, Inc.
R&D Insights: How Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation Allocate Funds
Research and Development Investment: Corcept Therapeutics Incorporated vs Dynavax Technologies Corporation
Rhythm Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?
Comparing Innovation Spending: Xenon Pharmaceuticals Inc. and Dynavax Technologies Corporation